A Phase I, Three-Period, Three-Way, Randomized, Open-Label, Single-Dose, Cross-Over, Comparative Bioavailability Study of Dihydroergotamine Mesylate (DHE) Administered by I123 Precision Olfactory Delivery (PODTM) Device Nasal Spray, DHE for Injection (Intravenous), and Migranal Nasal Spray in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 31 Oct 2017
At a glance
- Drugs Dihydroergotamine mesilate (Primary) ; Dihydroergotamine mesilate (Primary)
- Indications Migraine
- Focus Pharmacokinetics
- 31 Oct 2017 According to a Impel NeuroPharma media release, the first patient was dosed in this clinical trial.
- 31 Oct 2017 Status changed from not yet recruiting to recruiting, according to a Impel NeuroPharma media release.
- 05 Oct 2017 New trial record